This is the authors' abstract. We don't add key points for this paper.
A high-performance liquid chromatography-fluorescence detection (HPLC-FLD) method for determination of the fluoroquinolones norfloxacin (NOR), ciprofloxacin (CIP), levofloxacin (LEVO), and moxifloxacin (MOXI) in human plasma has been successfully developed. The detection was optimized with a dual wavelength excitation and emission fluorescence detector. Analytical wavelengths of λex/λem = 290/500 nm (for LEVO and MOXI) and λex/λem = 280/445 nm (for NOR and CIP) were found when measuring fluoroquinolones in the mixture. The plasma sample was pre-treated during the deproteinization step using methanol. This method was validated by linearity in the ranges of 0.05-15; 0.05-10; 0.05-15; and 0.10-10 μg ml-1 with limits of detection of 0.0071; 0.0080; 0.0074; and 0.0171 μg ml-1 for NOR, CIP, LEVO, and MOXI, respectively. Further, the HPLC-FLD method was proven to be precise and accurate with relative standard deviations lower than 6% and recoveries ranging from 92.5-105.4% for all four fluoroquinolones. Therefore, the proposed HPLC-FLD method provides an alternative approach for the simultaneous analysis of fluoroquinolones in plasma
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: